Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies.
作者信息
Friedli Christoph, Diem Lara, Hammer Helly, Kamber Nicole, Suter-Riniker Franziska, Leib Stephen, Chan Andrew, Hirzel Cédric, Hoepner Robert, Salmen Anke
机构信息
Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, 3010, Switzerland.
Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
出版信息
Ther Adv Neurol Disord. 2021 May 18;14:17562864211016641. doi: 10.1177/17562864211016641. eCollection 2021.
Abstract
摘要
相似文献
1
Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies.接受抗CD20疗法治疗的患者，新冠病毒核酸检测（COVID-19-PCR）鼻咽拭子呈阳性后，严重急性呼吸综合征冠状病毒2（SARS-CoV2）抗体呈阴性。
Ther Adv Neurol Disord. 2021 May 18;14:17562864211016641. doi: 10.1177/17562864211016641. eCollection 2021.
2
The value of anal swab RT-PCR for COVID-19 diagnosis in adult Indonesian patients.成人印度尼西亚患者肛拭子 RT-PCR 检测 COVID-19 的价值。
BMJ Open Gastroenterol. 2021 May;8(1). doi: 10.1136/bmjgast-2020-000590.
3
Comparative evaluation of nasopharyngeal swab and saliva specimens for the molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19.比较日本 COVID-19 患者鼻咽拭子和唾液标本用于 SARS-CoV-2 RNA 分子检测的效果。
J Infect Chemother. 2021 Jan;27(1):126-129. doi: 10.1016/j.jiac.2020.09.027. Epub 2020 Sep 30.
4
Diagnostic testing for SARS-CoV-2 infection in HHT patients: nasopharyngeal versus oropharyngeal swab.遗传性出血性毛细血管扩张症患者 SARS-CoV-2 感染的诊断检测：鼻咽拭子与口咽拭子比较。
Orphanet J Rare Dis. 2020 Dec 18;15(1):350. doi: 10.1186/s13023-020-01628-w.
5
Assessment of Multiplex Digital Droplet RT-PCR as a Diagnostic Tool for SARS-CoV-2 Detection in Nasopharyngeal Swabs and Saliva Samples.评估多重数字液滴 RT-PCR 作为鼻咽拭子和唾液样本中 SARS-CoV-2 检测的诊断工具。
Clin Chem. 2021 Apr 29;67(5):736-741. doi: 10.1093/clinchem/hvaa323.
6
The presence of SARS-CoV2 antibodies in MS patients.多发性硬化症患者体内存在 SARS-CoV2 抗体。
Mult Scler Relat Disord. 2021 May;50:102793. doi: 10.1016/j.msard.2021.102793. Epub 2021 Jan 23.
7
An alternative way to perform diagnostic nasopharyngeal swab for SARS-CoV-2 infection.进行 SARS-CoV-2 感染诊断性鼻咽拭子检查的另一种方法。
Am J Otolaryngol. 2021 Mar-Apr;42(2):102828. doi: 10.1016/j.amjoto.2020.102828. Epub 2020 Nov 17.
8
Upper respiratory tract sampling in COVID-19.新型冠状病毒肺炎中的上呼吸道采样
Malays J Pathol. 2020 Apr;42(1):23-35.
9
Necessity for detection of SARS-CoV-2 RNA in multiple types of specimens for the discharge of the patients with COVID-19.有必要从多种类型的标本中检测 SARS-CoV-2 RNA，以用于出院新冠病毒感染患者。
J Transl Med. 2020 Nov 2;18(1):411. doi: 10.1186/s12967-020-02580-w.
10
Clinical Diagnostic Study of a Novel Injection Molded Swab for SARS-Cov-2 Testing.一种用于新型冠状病毒检测的新型注塑拭子的临床诊断研究
Infect Dis Ther. 2021 Jun;10(2):1015-1022. doi: 10.1007/s40121-020-00391-6. Epub 2021 Jan 11.
引用本文的文献
1
Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study.多发性硬化症和视神经脊髓炎谱系障碍患者对SARS-CoV-2疫苗接种的体液反应：一项真实世界研究
Neurol Ther. 2024 Feb;13(1):153-164. doi: 10.1007/s40120-023-00572-8. Epub 2023 Dec 14.
2
COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.视神经脊髓炎谱系疾病（NMOSD）患者的 COVID-19 易感性和结局：系统评价和荟萃分析。
Mult Scler Relat Disord. 2022 Jan;57:103359. doi: 10.1016/j.msard.2021.103359. Epub 2021 Nov 1.
3
Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis.多发性硬化症患者接种SARS-CoV-2疫苗后COVID-19的临床特征和结局
Mult Scler J Exp Transl Clin. 2021 Nov 26;7(4):20552173211057110. doi: 10.1177/20552173211057110. eCollection 2021 Oct.
4
Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.多发性硬化症患者接种 SARS-CoV-2 mRNA 疫苗后的体液免疫：距上次利妥昔单抗输注时间和首次偶发性补种的相关性。
J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):19-22. doi: 10.1136/jnnp-2021-327612. Epub 2021 Oct 20.
5
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.体液免疫应答继多发性硬化症抗 CD20 治疗后接受 SARS-CoV-2 mRNA 疫苗接种。
Mult Scler Relat Disord. 2021 Nov;56:103251. doi: 10.1016/j.msard.2021.103251. Epub 2021 Sep 9.
本文引用的文献
1
Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity.抗严重急性呼吸综合征冠状病毒 2 抗体反应的幅度和动力学及其与疾病严重程度的关系。
Clin Infect Dis. 2021 Jan 27;72(2):301-308. doi: 10.1093/cid/ciaa979.
2
Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?超越 COVID-19：接受抗 CD20 治疗的多发性硬化症/视神经脊髓炎谱系疾病患者是否会产生 SARS-CoV2 抗体？
Mult Scler Relat Disord. 2020 Nov;46:102482. doi: 10.1016/j.msard.2020.102482. Epub 2020 Sep 3.
3
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.COVID-19 疫苗接种准备与自身免疫性疾病中的抗 CD20 耗竭疗法。
Clin Exp Immunol. 2020 Nov;202(2):149-161. doi: 10.1111/cei.13495. Epub 2020 Aug 1.
4
COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.7 例接受抗 CD20 治疗的多发性硬化症患者合并 COVID-19。
Mult Scler Relat Disord. 2020 Sep;44:102306. doi: 10.1016/j.msard.2020.102306. Epub 2020 Jun 15.
5
Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.新型冠状病毒肺炎疫苗：来自其他冠状病毒毒株的经验教训。
Infect Dis Ther. 2020 Jun;9(2):255-274. doi: 10.1007/s40121-020-00300-x. Epub 2020 Apr 23.
Zotero 插件